Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant chemotherapy guided by postoperative ctDNA in high-risk rectal cancer (REACT)
2024-517700-12-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in rectal cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Disease-free survival (intention-to-treat). Planned start Dec 2025; status: authorised.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-517700-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517700-12-00.